By the Top Tier Newswire AI Desk · September 2, 2026 at 10:16 AM ET · reviewed against 11 wire stories
MODERNA INC (MRNA) is down -4.15% in the latest session. Our newswire has captured 11 stories on MRNA across 9 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why MRNA stock is down today
Moderna Inc (MRNA) shares fell 4.15% to $147.87 in early trading on September 2, 2026. The decline followed a -2.4% opening gap and a volatile session that saw the stock swing between a high of $156.42 and a low of $147.21. The move appears to reflect broader market uncertainty and a lack of momentum in the biotech sector, despite recent developments such as Moderna’s $3 billion convertible notes offering.
What Happened
Moderna’s stock opened at $150.64, down from the previous close of $154.27, and has traded in a wide range since. The stock’s decline followed a recent stretch of strong performance, including a 143% gain in one month, but has now fallen -5.5% over the last eight sessions. The company announced the completion of a $3 billion private offering of 0.00% Convertible Senior Notes due 2032 on September 1, 2026, according to a SEC 8-K filing. This financing move may have been intended to bolster its balance sheet amid ongoing losses, with the company reporting a net loss of $8.01 per share in the trailing twelve months and a revenue decline of 27.6%.
What The Data Shows
Intraday volume of 4.2 million shares is 0.3 times the 3-month average, suggesting limited immediate follow-through from the financing announcement. The stock has printed six fresh 52-week lows and two 52-week highs on September 2, indicating a volatile price environment. Options activity has skewed heavily to calls, with $38.7 million in call premium versus $1.8 million in puts. Insiders have sold $35.2 million in shares over the last 90 days, with the CEO, Stephane Bancel, selling on August 5. Meanwhile, retail traders have noted Moderna’s recent rally and speculated on its potential at forums like r/wallstreetbets, though such commentary does not reflect company actions.
What To Watch
The stock is currently unprofitable with a net margin of -141.4% and a beta of 0.90. Investors should monitor the company’s upcoming conference presentations in September 2026 and any further developments from the biotech sector.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding […]
11d agoTipRanksBEARISH 24General
Moderna Raises $3 Billion via Convertible Notes Offering
Moderna ( ($MRNA) ) just unveiled an update. On September 1, 2026, Moderna completed a $3.0 billion private offering of 0.00% Convertible Senior Notes due 2032, iss...
11d agoSEC 8-KNEUTRAL 50General
Moderna, Inc. (MRNA) files 8-K
Filed: 2026-09-01 AccNo: 0001193125-26-378505 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
11d agoMarketChameleonBULLISH 56Analyst
Why Selling This Iron Condor in MRNA Makes Sense for a $6.37 Credit
Take a deep dive into some of Market Chameleon's most relevant trade ideas. This article includes detailed breakdowns of strategies and payout diagrams for MRNA from September 01, 2026.
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
11d agoYahoo TopBULLISH 63General
S&P 500 biggest August 2026 winners: Moderna, software stocks
12d agoStockTitanBULLISH 56Product/PR
Moderna to Present at Upcoming Conferences in September 2026
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →